Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), announced on Tuesday that the US Food and Drug Administration (FDA) has accepted the Biologics License Application for AVT06, a proposed biosimilar to Eylea (aflibercept).
The regulatory review is expected to conclude in the fourth quarter of 2025.
Alvotech is developing AVT06 as a biosimilar to Eylea (aflibercept) 2 mg, used for treating eye disorders such as neovascular (wet) age-related macular degeneration, macular oedema and diabetic retinopathy. The company is also advancing AVT29, a biosimilar candidate for Eylea HD (aflibercept) 8 mg, for which Teva Pharmaceuticals holds US commercialisation rights.
A confirmatory clinical study for AVT06 met its primary endpoint, demonstrating therapeutic equivalence, safety and immunogenicity compared to Eylea.
In 2024, combined sales of Eylea and Eylea HD in the United States reached USD4.77bn.
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth
NICE endorses AOTI's TWO2 therapy for diabetic foot ulcers
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
OptiBiotix signs distribution deal with major weight management company
GoodRx partners with Novo Nordisk to offer Ozempic and Wegovy at USD499 per month